

# Oral chemotherapy versus intravenous chemotherapy in limited or extensive small cell lung cancer

<b>Submission date</b> 01/07/2001	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/07/2001	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/09/2017	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr - -

### Contact details

UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

LU309

# Study information

## Scientific Title

Oral chemotherapy versus intravenous chemotherapy in limited or extensive small cell lung cancer: a randomised controlled trial

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Not Specified

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Lung (small cell)

## Interventions

1. Oral Regimen: Oral etoposide and cyclophosphamide given over 5 days every 3 weeks.
2. Intravenous Regimen: Intravenous combination of three or more drugs routinely used in the centre with the usual dose reduction. A standard alternative is adriamycin, cyclophosphamide and vincristine (VAC) repeated every 3 weeks.

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/1995

**Completion date**

31/12/2000

**Reason abandoned (if study stopped)**

Objectives no longer viable

## **Eligibility**

**Key inclusion criteria**

1. Histologically or cytologically proven small cell lung cancer
2. No previous or concurrent malignancy
3. Fit to receive chemotherapy
4. No prior chemotherapy or radiotherapy
5. No biochemical or haematological abnormalities which would preclude chemotherapy

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1995

**Date of final enrolment**

31/12/2000

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**  
**UKCCCR Register Co-ordinator**  
London  
United Kingdom  
NW1 2DA

## **Sponsor information**

### **Organisation**

Cancer Research UK (CRUK) (UK)

### **Sponsor details**

PO Box 123  
Lincoln's Inn Fields  
London  
United Kingdom  
WC2A 3PX  
+44 (0)207 317 5186  
kate.law@cancer.org.uk

### **Sponsor type**

Charity

### **Website**

<http://www.cancer.org.uk>

### **ROR**

<https://ror.org/054225q67>

## **Funder(s)**

### **Funder type**

Charity

### **Funder Name**

Cancer Research UK

### **Alternative Name(s)**

CR\_UK, Cancer Research UK - London, CRUK

### **Funding Body Type**

Private sector organisation

### **Funding Body Subtype**

Other non-profit organizations

### **Location**

United Kingdom

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration

### **Study outputs**

<b>Output type</b>	<b>Details</b>	<b>Date created</b>	<b>Date added</b>	<b>Peer reviewed?</b>	<b>Patient-facing?</b>
<a href="#">Interim results article</a>	interim results	31/08/1996		Yes	No